PURPOSE: Vascular endothelial growth factor (VEGF) is an important factor involved in angiogenesis. Many studies have reported that the expression of VEGF in breast cancer is an unfavorable prognostic factor. However, there are few studies that have analyzed blood VEGF levels because most used serum VEGF, generally thought to originate from platelets. We measured plasma VEGF levels, which evaluate the level of tumor-derived VEGF, in various breast diseases. METHOD: We analyzed 15 patients with benign breast disease, 187 patients with primary breast cancer, 32 patients with no postoperative recurrence, and 56 patients with recurrence. Plasma VEGF levels were measured by ELISA. RESULTS: Plasma VEGF levels were higher in malignant than in benign breast disease, and were also high in patients with recurrence or distant metastasis. In primary cases, higher VEGF levels were clearly correlated with menopause and overexpression of p53, and postmenopausal patients with high levels had a significantly lower disease-free survival rate. CONCLUSION: These results suggest that plasma VEGF levels in breast cancer have a clinical significance in that they are associated with the extent or metastasis of malignant lesions and are involved in angiogenesis in postmenopausal patients.
PURPOSE:Vascular endothelial growth factor (VEGF) is an important factor involved in angiogenesis. Many studies have reported that the expression of VEGF in breast cancer is an unfavorable prognostic factor. However, there are few studies that have analyzed blood VEGF levels because most used serum VEGF, generally thought to originate from platelets. We measured plasma VEGF levels, which evaluate the level of tumor-derived VEGF, in various breast diseases. METHOD: We analyzed 15 patients with benign breast disease, 187 patients with primary breast cancer, 32 patients with no postoperative recurrence, and 56 patients with recurrence. Plasma VEGF levels were measured by ELISA. RESULTS: Plasma VEGF levels were higher in malignant than in benign breast disease, and were also high in patients with recurrence or distant metastasis. In primary cases, higher VEGF levels were clearly correlated with menopause and overexpression of p53, and postmenopausal patients with high levels had a significantly lower disease-free survival rate. CONCLUSION: These results suggest that plasma VEGF levels in breast cancer have a clinical significance in that they are associated with the extent or metastasis of malignant lesions and are involved in angiogenesis in postmenopausal patients.
Authors: Katherine W Reeves; Roberta B Ness; Roslyn A Stone; Joel L Weissfeld; Victor G Vogel; Robert W Powers; Francesmary Modugno; Jane A Cauley Journal: Cancer Causes Control Date: 2008-11-06 Impact factor: 2.506
Authors: Seung Hoan Choi; Daniela Ruggiero; Rossella Sorice; Ci Song; Teresa Nutile; Albert Vernon Smith; Maria Pina Concas; Michela Traglia; Caterina Barbieri; Ndeye Coumba Ndiaye; Maria G Stathopoulou; Vasiliki Lagou; Giovanni Battista Maestrale; Cinzia Sala; Stephanie Debette; Peter Kovacs; Lars Lind; John Lamont; Peter Fitzgerald; Anke Tönjes; Vilmundur Gudnason; Daniela Toniolo; Mario Pirastu; Celine Bellenguez; Ramachandran S Vasan; Erik Ingelsson; Anne-Louise Leutenegger; Andrew D Johnson; Anita L DeStefano; Sophie Visvikis-Siest; Sudha Seshadri; Marina Ciullo Journal: PLoS Genet Date: 2016-02-24 Impact factor: 5.917
Authors: Aoife J Lowery; Karl J Sweeney; Alan P Molloy; Emer Hennessy; Catherine Curran; Michael J Kerin Journal: BMC Cancer Date: 2008-09-30 Impact factor: 4.430